Figure 3. A heatmap of mean
scores per type of guideline across stakeholder groups (green indicates
higher acceptance, red lower)
A subgroup analysis (Figure 4) revealed that the Blood Products and
Quality Working Parties have a lower acceptance level for comments
overall. The results were similar to guidelines that are authored by
multiple working parties. The Biosimilar Medicines and Pharmacokinetic
Working Parties have been receptive towards comments from governmental
authorities, but less so for others. The Biologics, Cardiovascular,
Safety and Rheumatology/Immunology Working Parties do not reflect any
trends with scores above or close to 1 for other stakeholders than
government.